Research & Development Home / Services / Research & Development R&D FinVector’s Research and Development department is at the forefront for process development activities in advanced therapies. FinVector’s development facilities, matched with the extensive experience of our scientific team, enables us to work with a broad range of viral vectors, especially Adenoviruses (recombinant, oncolytic), Adeno Associated Virus (AAV) and Lentivirus. FinVector has developed several manufacturing processes from small flask scale to commercial scale utilizing either serum free suspension bioreactor approach or controlled and disposable fixed bed bioreactor. Scalable and cost effective large scale purification is based on chromatography and tangential flow filtration. Along the process development, product specific assays are developed during the early stage. FinVector has several areas that are dedicated for viral vector process development suitable for upstream and downstream work. Pilot facility is designed for process scale up activities as a last step towards the GMP. Close contact of Finvector´s R&D, GMP manufacturing and quality/regulatory teams guarantees high quality reproducible products for the international market. Contact Microkatu 1 S FI-70210 Kuopio , Finland +358 (0)17 240 875 info@finvector.com Contact Us Alert Channel News & Events Careers Privacy & Cookie Policy Etelä-Savo Centre for Economic Development, Transport and the Environment has granted FinVector Oy a total of EUR 6,555,000 for the construction of new pharmaceutical manufacturing facility.

Home / Services / Regulatory FinVector regulatory team is fully versant in the standards that are required for Gene Therapy and Viral Vectors. FinVector has written CMC (Quality) sections for clinical trials of its own products and Market Authorisation Applications, and can provide assistance to the client. As FinVector has worked on Gene Therapy products that have undergone late stage phase III clinical trial as well as early stage clinical trials, FinVector can bring this direct knowledge to assist you in your CMC submission and all stages of regulatory submissions. Contact Microkatu 1 S FI-70210 Kuopio , Finland +358 (0)17 240 875 info@finvector.com Contact Us Alert Channel News & Events Careers Privacy & Cookie Policy Etelä-Savo Centre for Economic Development, Transport and the Environment has granted FinVector Oy a total of EUR 6,555,000 for the construction of new pharmaceutical manufacturing facility.